News NICE rejects Shire pancreatic cancer drug Onivyde not eligible for Cancer Drugs Fund, says NICE.
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Expert questions survival benefit of cancer drugs Spending vast sums to extend life by weeks or months may be unethical, says doctor.
News BMS and Infinity look to boost Opdivo in lung cancer Companies look for combinations in lung cancer and other tumours.
News NICE rejects Amgen's Kyprolis in multiple myeloma NICE rejects drug despite efficacy and quality of life evidence.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
